Takeda sees cell, gene therapy in its future. Is it too late? – BioPharma Dive
Posted: November 21, 2019 at 5:44 am
Thanks to a $62 billion acquisition of Shire, Takeda is one of the world's largest developers of rare disease drugs.
Despite that, the 238-year-old Japanese pharmaceutical company lacks any mid- or late-stage cell or gene therapies, two technologies that figure to play a large role in how many rare cancers and inherited diseases will eventually be treated.
It's a mismatch Takedais putting substantial effort into addressing. Last week, executives made cell and gene therapy a notable focus of the company's first R&D day since closing its Shire deal.
"We have a world-class gene therapy platform," Dan Curran, head of Takeda's rare disease therapeutic area unit, told investors and Wall Street analysts gathered in New York city.
"We intend to build on that over the next five years. Because as we look to lead in the second half of [next]decade, we believe patients will demand and we can deliver transformative and curative therapies to patients globally."
But right now that's just an ambition. While Takedahas begun to explore how it can improve on current gene therapies, its candidates are early stage and lag their would-be competitors.
"Our heme A program we're behind. Our heme B program we're behind," admitted Curran in an interview. "But we're behind the first generation and when has there only been one generation of anything?"
Takeda's hemophilia A program is currently in Phase 1, with the hemophilia B candidate about to join it in human testing well back from leaders BioMarin Pharmaceutical, Spark Therapeutics and SangamoTherapeutics in hemophilia A and UniQure in hemophilia B.
Curran laid out three priorities for Takeda'spush: exploring whether gene therapy, typically pitched as a one-time treatment, can be re-dosed; lowering the doses currently used for first-generation therapies; and developing alternative gene delivery vehicles than the adeno-associatedand lentiviralvectors that are predominant today.
"We need to figure out how to re-dose AAVvectors if we want to provide functional cures for patients for the rest of their lives."
How long a gene therapy's benefit lasts is a critical question. In theory, it could last decades or potentially for life, depending on the treatment's target.
But clinical evidence presented to date suggests that benefit for some therapies could wane over time. BioMarin, for example, presented data this year that it argued is proof its gene therapy could raise Factor VIII expression levels in patients with hemophilia A above the threshold for mild disease for at least eight years a long time, to be sure, but not life-long.
Still, it's an unusual objective. Much of gene therapy's promise lies in the potential for it to be given just once and still deliver lasting benefits. And the therapies that have reached market most notably Spark Therapeutics' Luxturna, Novartis' Zolgensma and Bluebird bio's Zynteglo are among the most expensive drugs to ever reach market. Were a gene therapy to be re-dosed, the current value proposition those drugmakers describe would need to be re-evaluated.
Curran recognizes that bringing down costs substantially will be essential to any attempt to advance a multi-use gene therapy. But Takeda might have an advantage. In buying Shire, the pharma inherited a viral vector manufacturing plant, originally built by Baxalta, that Curran calls the company's "best kept secret."
"It's an enormous competitive advantage," he said, adding that Takeda believes it's among the industry's top three facilities by production capacity. "Roche trying to acquire Spark, Novartis and AveXis a significant component of value of those transactions was that these companies had actually invested in manufacturing capabilities."
Curran emphasized that Takeda's ambitions in gene therapy will require it to partner with academic leaders in the field, a playbook that it's followed over the past three years as it's worked to expand into cell therapy.
"In the cell space, there's more innovation you can bring up into proof of principle milestones in academia," said Andy Plump,Takeda'shead of R&D, in an interview.
"An academic can manipulate a cell, but it's very hard in an academic setting to optimize a small molecule," he added. "This is a space where Novartis, and now we, have been quite successful in creating those relationships."
Takeda has put partnerships in place with Japan's Center for iPS Cell Research and Application, GammaDelta, Noile-Immune Biotech, Memorial Sloan Kettering Cancer Center and, just this month, The University of Texas MD Anderson Cancer Center.
That last collaboration gives Takeda access to a chimeric antigen receptor-directed natural killer, or NK, cell therapy.The drugmaker believes NK cells could offer advantages over the T cells modified to create the currently available cell therapies Kymriah and Yescarta.
Most notably, MD Anderson's approach uses NK cells isolated from umbilical cord blood, rather than extracting T cells from each individual patient a time-consuming and expensive process that has complicated the market launch of Kymriah and Yescarta. Cord blood-derived NK cells are designed to be allogeneic, or administered "off the shelf."
Additionally, CAR NK cells haven't been associated (yet) with cytokine release syndrome or neurotoxicity, two significant side effects often associated with CAR-T cell therapies. That could help Takeda position its cell therapies as an outpatient option.
"Even if we were a company that entered a little bit later into the immuno-oncology space, we've very much tried to turn this into an advantage," said Chris Arendt, head of Takeda's oncology drug discovery unit, at the company's event.
"We believe we have a chance to establish a leadership position rather than jumping on the bandwagon and being a follower."
While Takeda's choice to pursue NK cell therapy stands out, its choice of target does not. TAK-007, a drug candidate from MD Anderson that is now Takeda's lead cell therapy program, is aimed at a cell surface protein called CD19 that's found in leukemias and lymphomas.
Both Yescarta and Kymriah target CD19, and a recent count by the Cancer Research Institute tracked 181 cell therapy projects aimed at the antigen.
Takeda is planning to advance TAK-007 into pivotal studies in two types of lymphoma and chronic lymphocytic leukemia by 2021, with a potential filing for approval in 2023.
By then, Kymriah and Yescarta will have been on the market for six years and current bottlenecks in cell therapy treatment could be solved, helping both Takeda's potential entry as well as the host of competitors it will likely face.
Next year will be a test of how productive Takeda'scell therapy unit can be. In addition to TAK-007, the pharmaexpects to have four other CAR-T and gamma delta cell therapies in the clinic, two of which will target solid tumors.
Cell and gene therapy are part of what Takeda calls its "second wave" of R&D projects, a group of early-stage drugs and programs that it sees as progressing to regulatory stages by 2025 or later.
In the nearer term, the drugmakeris advancing a "first wave" of clinical candidates that it told investors will deliver 14 new molecular entities by 2024. Five of those will come in rare disease, with the others spread across oncology, neuroscience, gastro-enterology and vaccines.
"We think the cascade of news coming forward on these programs will transform how people view Takeda," Curran said.
More importantly to the investors gathered in New York, Takeda expects these experimental drugs will eventually earn $10 billion in peak annual sales, which would represent a sizable addition to a business that generated $30 billion in sales last year.
Read the original:
Takeda sees cell, gene therapy in its future. Is it too late? - BioPharma Dive
- Ying Liu discusses IPS cell therapy for ALS [Last Updated On: August 6th, 2011] [Originally Added On: August 6th, 2011]
- IPs cells Part 1 [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Stem Cell Implications for ALS (Amyotrophic Lateral Sclerosis) [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- A Century of Stem Cells - Johns Hopkins Medicine [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Myelin Repair Foundation on Stem Cell Research [Last Updated On: September 6th, 2011] [Originally Added On: September 6th, 2011]
- Jeanne Loring talks about stem cells, part 2 [Last Updated On: September 6th, 2011] [Originally Added On: September 6th, 2011]
- IPs Cells Part 4 [Last Updated On: September 6th, 2011] [Originally Added On: September 6th, 2011]
- Embryonic Stem Cells From Skin: Making Old Cells Young [Last Updated On: September 7th, 2011] [Originally Added On: September 7th, 2011]
- National Medical Report [Last Updated On: September 7th, 2011] [Originally Added On: September 7th, 2011]
- National Medical Report [Last Updated On: September 7th, 2011] [Originally Added On: September 7th, 2011]
- Jeanne Loring talks about stem cells, part 3 [Last Updated On: September 7th, 2011] [Originally Added On: September 7th, 2011]
- Kristopher Nazor 2 [Last Updated On: September 9th, 2011] [Originally Added On: September 9th, 2011]
- Myelin Repair Foundation on Stem Cell Research [Last Updated On: September 9th, 2011] [Originally Added On: September 9th, 2011]
- Dr. Oz to Oprah and Michael J Fox: "The stem cell debate is dead." [Last Updated On: September 10th, 2011] [Originally Added On: September 10th, 2011]
- Dr. Oz to Oprah and Michael J Fox: "The stem cell debate is dead." [Last Updated On: September 10th, 2011] [Originally Added On: September 10th, 2011]
- Andalusian Stem Cell Bank [Last Updated On: September 10th, 2011] [Originally Added On: September 10th, 2011]
- IPs cells Part3 [Last Updated On: September 10th, 2011] [Originally Added On: September 10th, 2011]
- Andalusian Stem Cell Bank [Last Updated On: September 11th, 2011] [Originally Added On: September 11th, 2011]
- IPs Cells Part 4 [Last Updated On: September 11th, 2011] [Originally Added On: September 11th, 2011]
- iPS Stem Cell-Based Treatment of Epidermolysis Bullosa [Last Updated On: September 12th, 2011] [Originally Added On: September 12th, 2011]
- Jeanne Loring talks about stem cells, part 1 [Last Updated On: September 12th, 2011] [Originally Added On: September 12th, 2011]
- Jeanne Loring talks about stem cells, part 2 [Last Updated On: September 12th, 2011] [Originally Added On: September 12th, 2011]
- Jeanne Loring talks about stem cells, part 3 [Last Updated On: September 12th, 2011] [Originally Added On: September 12th, 2011]
- Kristopher Nazor 2 [Last Updated On: September 12th, 2011] [Originally Added On: September 12th, 2011]
- Stem Cell Implications for ALS (Amyotrophic Lateral Sclerosis) [Last Updated On: September 12th, 2011] [Originally Added On: September 12th, 2011]
- IPs cells Part 2 [Last Updated On: September 13th, 2011] [Originally Added On: September 13th, 2011]
- Cellular Reprogramming Stem Cell Domain Name For Sale! - CellularReprogramming.com [Last Updated On: September 14th, 2011] [Originally Added On: September 14th, 2011]
- Cellular Reprogramming Stem Cell Domain Name For Sale! - CellularReprogramming.com [Last Updated On: September 19th, 2011] [Originally Added On: September 19th, 2011]
- IPs cells Part 2 [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Healthy Body = Functional Body. Hollywood Look Side Effect: Healthy Function [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Hollywood, Smith [Last Updated On: October 1st, 2011] [Originally Added On: October 1st, 2011]
- Manning, Owens Try Stem Cell Therapy [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Epidermolysis Bullosa: Corrected iPS Stem Cell-Based Therapy - Video [Last Updated On: October 13th, 2011] [Originally Added On: October 13th, 2011]
- Spinal Cord Injury - Embryonic Stem Cells - Dr. Keirstead - Video [Last Updated On: October 15th, 2011] [Originally Added On: October 15th, 2011]
- Introduction to Stem Cells - Video [Last Updated On: October 15th, 2011] [Originally Added On: October 15th, 2011]
- Parkinson's Disease: Progress and Promise in Stem Cell Research - Video [Last Updated On: October 16th, 2011] [Originally Added On: October 16th, 2011]
- Visions Episode 92: Stem Cells Discovery - Video [Last Updated On: October 16th, 2011] [Originally Added On: October 16th, 2011]
- James Bond Sam Botta Roger Moore I Married A Beautiful Woman - Video [Last Updated On: October 17th, 2011] [Originally Added On: October 17th, 2011]
- James Bond Sam Botta Roger Moore I Married A Beautiful Woman - Video [Last Updated On: October 18th, 2011] [Originally Added On: October 18th, 2011]
- induced pluripotent stem (iPS) cells: Part 2 - Video [Last Updated On: October 25th, 2011] [Originally Added On: October 25th, 2011]
- TEACHERS OWN CALPERS/GID Managed Apartments, Teachers EVICTING Paraplegic - Video [Last Updated On: November 5th, 2011] [Originally Added On: November 5th, 2011]
- TEACHERS OWN CALPERS/GID Managed Apartments, Teachers EVICTING Paraplegic - Video [Last Updated On: November 6th, 2011] [Originally Added On: November 6th, 2011]
- Stem Cells Could Repair Heart [11-14-2011] - Video [Last Updated On: November 21st, 2011] [Originally Added On: November 21st, 2011]
- Advantages Seroquel - Video [Last Updated On: December 6th, 2011] [Originally Added On: December 6th, 2011]
- induced pluripotent stem (iPS) cells: Part 2 - Video [Last Updated On: December 6th, 2011] [Originally Added On: December 6th, 2011]
- Advantages Seroquel - Video [Last Updated On: December 6th, 2011] [Originally Added On: December 6th, 2011]
- stem cell research - Video [Last Updated On: December 7th, 2011] [Originally Added On: December 7th, 2011]
- Ian Wilmut discusses stem cell and direct cellular transformation therapy - Video [Last Updated On: December 7th, 2011] [Originally Added On: December 7th, 2011]
- Lec 22 | MIT 16.885J Aircraft Systems Engineering, Fall 2005 - Video [Last Updated On: December 7th, 2011] [Originally Added On: December 7th, 2011]
- Paralyzed rat walks with own stem cells in 11 wks. - Video [Last Updated On: December 7th, 2011] [Originally Added On: December 7th, 2011]
- Lec 22 | MIT 16.885J Aircraft Systems Engineering, Fall 2005 - Video [Last Updated On: December 8th, 2011] [Originally Added On: December 8th, 2011]
- Jeff Bluestone: Immune rejection of stem cell transplants - Video [Last Updated On: December 8th, 2011] [Originally Added On: December 8th, 2011]
- Advances in Stem Cell Research: Shinya Yamanaka - Video [Last Updated On: December 10th, 2011] [Originally Added On: December 10th, 2011]
- 2011 Summit: Stem Cells, Reprogramming and Personalized Medicine, Rudolf Jaenisch, MD - Video [Last Updated On: December 14th, 2011] [Originally Added On: December 14th, 2011]
- Parkinson's Disease: Advancing Stem Cell Therapies - 2011 CIRM Grantee Meeting - Video [Last Updated On: January 19th, 2012] [Originally Added On: January 19th, 2012]
- Parkinson's Disease: Advancing Stem Cell Therapies - 2011 CIRM Grantee Meeting - Video [Last Updated On: January 20th, 2012] [Originally Added On: January 20th, 2012]
- Professor Alan Trounson - World focus on stem cell research - Video [Last Updated On: January 26th, 2012] [Originally Added On: January 26th, 2012]
- Professor Alan Trounson - World focus on stem cell research - Video [Last Updated On: January 26th, 2012] [Originally Added On: January 26th, 2012]
- Researchers turn skin cells into neural precusors, bypassing stem-cell stage [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- Skin cells turned into neural precusors, bypassing stem-cell stage [Last Updated On: February 1st, 2012] [Originally Added On: February 1st, 2012]
- “Wide-ranging applications for pluripotent stem cells” [Last Updated On: February 2nd, 2012] [Originally Added On: February 2nd, 2012]
- New era of medicine in the offing, says scientist [Last Updated On: February 5th, 2012] [Originally Added On: February 5th, 2012]
- EC transfers Basti Commissioner to pacify agitating IPS officers [Last Updated On: February 7th, 2012] [Originally Added On: February 7th, 2012]
- Radiation treatment transforms breast cancer cells into cancer stem cells [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- Radiation treatment generates cancer stem cells from less aggressive breast cancer cells, study suggests [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- Radiation Treatment Generates Cancer Stem Cells from Less Aggressive Breast Cancer Cells [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- Life Technologies Scientist Uma Lakshmipathy presents, "Solving Challenges in the Generation of Induced Pluripotent ... [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- Radiation therapy transforms breast cancer cells into cancer stem cells [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- Radiation treatment transforms breast cancer cells into cancer stem cells [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- Radiation treatment generates cancer stem cells from less aggressive breast cancer cells, study suggests [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- Life Technologies Scientist Uma Lakshmipathy presents, "Solving Challenges in the Generation of Induced Pluripotent ... [Last Updated On: February 15th, 2012] [Originally Added On: February 15th, 2012]
- Radiation Treatment Generates Cancer Stem Cells from Less Aggressive Breast Cancer Cells [Last Updated On: February 15th, 2012] [Originally Added On: February 15th, 2012]
- Horizon in new super-cell elite [Last Updated On: February 16th, 2012] [Originally Added On: February 16th, 2012]
- albuterol adverse effects - Video [Last Updated On: February 21st, 2012] [Originally Added On: February 21st, 2012]
- Presentations at the Society of Toxicology Annual Meeting Demonstrate Superior Predictivity of Cellular Dynamics ... [Last Updated On: March 8th, 2012] [Originally Added On: March 8th, 2012]
- A new approach to treating type I diabetes? Gut cells transformed into insulin factories [Last Updated On: March 11th, 2012] [Originally Added On: March 11th, 2012]
- New approach to treating type 1 diabetes? Transforming gut cells into insulin factories [Last Updated On: March 11th, 2012] [Originally Added On: March 11th, 2012]
- New approach to treating type 1 diabetes? Transforming gut cells into insulin factories [Last Updated On: March 11th, 2012] [Originally Added On: March 11th, 2012]
- A new approach to treating type I diabetes? Gut cells transformed into insulin factories [Last Updated On: March 11th, 2012] [Originally Added On: March 11th, 2012]
- Gut cells transformed into insulin factories 'could help to treat type I diabetes' [Last Updated On: March 12th, 2012] [Originally Added On: March 12th, 2012]